Assuntos
Monitorização Ambulatorial da Pressão Arterial , Hipertensão/diagnóstico , Garantia da Qualidade dos Cuidados de Saúde/métodos , Anti-Hipertensivos/uso terapêutico , Humanos , Hipertensão/terapia , Reembolso de Incentivo , Estados Unidos , Hipertensão do Jaleco Branco/diagnóstico , Hipertensão do Jaleco Branco/terapiaAssuntos
Hipertensão/diagnóstico , Hipertensão/epidemiologia , Hipertensão do Jaleco Branco/diagnóstico , Hipertensão do Jaleco Branco/epidemiologia , África Subsaariana/epidemiologia , Análise Custo-Benefício , Humanos , Hipertensão/economia , Hipertensão/terapia , Programas de Rastreamento , Hipertensão do Jaleco Branco/economia , Hipertensão do Jaleco Branco/terapiaRESUMO
The term 'white coat' hypertension (WC-HTN) is intended to reflect the situation in which measurement of blood pressure (BP) by a health professional (often a physician in a white coat) in an office setting is found to be elevated in comparison with BP measured by a more consistent and less error-prone method such as ambulatory BP monitoring (ABPM), or home BP monitoring (HBPM). Office BP (also sometimes called 'casual BP') has formed the basis of clinical trials that confirm meaningful reductions in MI (25 %), stroke (40 %), and heart failure (50 %) with pharmacotherapy. Nonetheless, within clinical trials, a substantial minority of patients have been determined to have WC-HTN, for which treatment is not known to be of benefit, and is hence not indicated. Clinicians continue to have a good deal of uncertainty about the definition, consequences, course, and best management of WC-HTN. The intention of this communication is to address the top priority questions about WC-HTN to enable clinicians to become more confident in its identification and management.